Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow Jrheum on BlueSky
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
EditorialEditorial

Exercise Echocardiography as a Screening Tool in Systemic Sclerosis

MONICA MUKHERJEE and STEPHEN C. MATHAI
The Journal of Rheumatology May 2020, 47 (5) 643-645; DOI: https://doi.org/10.3899/jrheum.191249
MONICA MUKHERJEE
Johns Hopkins University, Division of Cardiology;
MD, MPH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mmukher2@jhmi.edu
STEPHEN C. MATHAI
Johns Hopkins University, Division of Pulmonary and Critical Care Medicine, Baltimore, Maryland, USA.
MD, MHS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • References
  • PDF
PreviousNext
Loading

In this issue of The Journal, Quinn, et al describe the utility of exercise echocardiography (EE) in the identification of patients with systemic sclerosis (SSc) deemed high risk for the development of pulmonary arterial hypertension (PAH)1. In a single-center observational study, the authors demonstrated that a significantly higher percentage of SSc patients with a persistently positive EE, as defined by an increase in right ventricular systolic pressure (RVSP) ≥ 20 mmHg with exercise, subsequently developed pulmonary hypertension (PH) compared with those who had persistently negative EE. The majority of patients with a baseline positive EE were found to have a persistently positive EE over time. However, interestingly, a proportion of those patients did not develop resting PAH. Similarly, 3 patients with baseline negative EE developed PAH shortly after initial testing, possibly representing a false-negative result. Because invasive hemodynamics with right heart catheterization (RHC) was not performed unless clinically indicated and was also performed up to 6 months following EE, it is difficult to ascertain the meaning of the present findings. Certainly, other SSc-specific features or biomarkers of increased risk in combination with positive EE need to be identified; however, lack of standardization in annual testing limits identification in this present study. In contrast, a negative EE may be helpful in identifying a group protected from developing PH in the future. This finding, if confirmed in larger studies, could lead to improved early detection strategies for patients with SSc at highest risk for development of PAH, and potentially other at-risk populations with connective tissue disease.

The current study is an extension of an original 2008 manuscript, also by Steen, et al, in which SSc patients at risk for PAH underwent EE to determine whether exercise-induced elevations in RVSP could elucidate those at greatest risk2. A major limitation of that study was designation of exertional elevation in RVSP ≥ 20 mmHg above a normal baseline as clinically significant, without any established consensus on accepted cutoff values; a limitation that is carried forward in the present study. The authors argue that the designation of a positive EE defined as RVSP ≥ 20 mmHg is more conservative than prior recommendations of RVSP ≥ 15 mmHg3. Current guidelines, however, recommend against this definition of exercise-induced PH (ex-PH), and in fact have removed this group entirely from the updated clinical classification owing to a lack of consensus on exercise protocols and key measurements required to establish the definition of ex-PH4. Further, there has been recent change in the invasive hemodynamic definition of PAH4, with mean pulmonary arterial pressures of ≥ 20 to < 25 mmHg representing an intermediate form of disease that is high risk for emerging PAH. However, there has not been a corresponding change to the definition of abnormal RVSP or delta change in RVSP with exercise by noninvasive methods, including EE.

To reliably assess exertional pulmonary hemodynamics, there must be correlation with invasive RHC to differentiate between pulmonary vascular versus left heart disease – an important consideration that therefore limits the clinical significance of the present findings. The use of a dichotomous RVSP cutoff in the determination of a positive result without RHC correlation therefore is nebulous. Additionally, +EE patients underwent RHC within an average of 6 months, which not only limits correlation with noninvasive estimates but also potentially introduces selection bias. Undoubtedly RVSP elevation occurs along a continuum, is subject to issues with technical acquisition due to the complex geometric configuration of the RV chamber and should also be considered in conjunction with some element of cardiac output or flow. Standard echocardiographic variables of RV function such as tricuspid annular plane systolic excursion (TAPSE), which have previously been shown to be predictive of mortality in SSc5, were not acquired in the present study. Further, the rapid drop in RVSP noted immediately following cessation of exercise may also lead to misclassification of positive and negative EE results by failing to identify those with high RVSP:flow relationships6.

Further, as demonstrated in the current study and prior studies of patients with SSc, various forms of PH can develop including PH related to left heart disease and PH related to lung disease in which the role for PAH-directed therapy is not established7,8. Despite EE being proposed as a screening tool, conventional echocardiographic techniques were not used in the present study, such as consideration of diastolic changes with exercise that may contribute to elevation in RVSP. Diastolic dysfunction is known to be highly prevalent in SSc9, and may be unmasked by exercise in this population as previously shown10,11,12. Thus, the utility of EE in patients with SSc who have significant interstitial lung disease at baseline or concomitant left heart disease, for example, is less clear. Last, it is difficult to ascertain the overall implications of these findings of a negative EE when 3 patients developed resting PAH shortly after a negative study. The lack of routine followup EE at prescribed intervals could lead to misclassification and ascertainment bias. Therefore, larger cohorts of patients with SSc are needed to power the negative and positive predictive value, sensitivity, and specificity of EE as a screening tool.

The concept of early detection techniques to assess for cardiopulmonary complications in SSc is exceedingly important and has a number of clinical implications that could affect the outcome of patients with SSc at risk for PAH. Cardiac involvement is prevalent in SSc and is clinically overt in approximately 10–30% of patients, depending on the diagnostic technique used13,14,15. Subclinical cardiac involvement, however, has been estimated at > 70%16, and therefore the prevalence may be underestimated, depending greatly on clinical suspicion and appropriate application of screening and diagnostic tools. Cardiopulmonary manifestations in this population are associated with increased morbidity and mortality, primarily due to the development of right ventricular (RV) dysfunction and associated PAH14,17. Despite routine clinical and echocardiographic monitoring, risk prediction of cardiac involvement and PAH in SSc remains poor18. We have previously shown that RV contractile abnormalities may be present when conventional echocardiographic measures are otherwise normal, regardless of noninvasive estimation of pulmonary pressures19, and that these metrics are predictive of mortality20 and responsive to PAH-directed therapies21. Although 2-dimensional echocardiography is a useful noninvasive modality in PH given its high specificity and high positive predictive value22, there may be improved screening accuracy in high-risk SSc patients when echocardiography is used in conjunction with pulmonary function testing, N-terminal pro-B-type natriuretic peptide levels23, and other clinical factors23,24,25. Unfortunately in the present study, there was no standardization of adjunctive testing performed such as pulmonary function testing, 6-minute walk test, or laboratory data that could be used simultaneously to help identify those SSc patients with high-risk features of emerging PAH.

Despite current guidelines that discourage the clinical classification of ex-PH, there is a growing body of evidence suggesting that ex-PH represents an important group of high-risk patients that require close serial monitoring for emerging RV failure and resting PAH. Apart from detection of ex-PH, EE is an important noninvasive modality that allows for assessment of RV contractile reserve, an independent predictor of mortality and poor prognosis26. Future longitudinal studies are required, however, to determine the utility of EE as a screening tool across a broad spectrum of patients with SSc at variable risk for PAH. Firmly establishing EE as a predictive tool in this at-risk population also requires establishment of test characteristics including expected biologic variability, reproducibility, sensitivity, specificity, negative and positive predictive values, and most importantly, correlation with simultaneous invasive hemodynamics with exercise. A particular strength of the present study is the longitudinal followup of patients, and the demonstration of the overall value of persistently positive versus persistently negative EE in the prediction of resting PAH. These findings serve as an important foundation for further studies with potential to affect clinical outcomes in SSc.

Quinn, et al1 report the novel finding that SSc patients with persistently positive EE are at increased risk of developing resting PAH during a mean 4-year followup period. While the objectives of this study are exceedingly important, there are a number of methodologic limitations that limit clinical implications and change in practice.

Footnotes

  • See Exercise echocardiography in SSc, page 708

  • The authors are supported by the Scleroderma Foundation (MM, SCM), CHEST Foundation (MM), US National Institutes of Health/National Heart, Lung, and Blood Institute U01HL125175 (MM), and R01HL114910 (MM, SCM).

REFERENCES

  1. 1.↵
    1. Quinn KA,
    2. Wappel SR,
    3. Kuru T,
    4. Steen VD
    . Exercise echocardiography predicts future development of pulmonary hypertension in a high-risk cohort of patients with systemic sclerosis. J Rheumatol 2020;47:708–13.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Steen V,
    2. Chou M,
    3. Shanmugam V,
    4. Mathias M,
    5. Kuru T,
    6. Morrissey R
    . Exercise-induced pulmonary arterial hypertension in patients with systemic sclerosis. Chest 2008;134:146–51.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Grünig E,
    2. Weissmann S,
    3. Ehlken N,
    4. Fijalkowska A,
    5. Fischer C,
    6. Fourme T,
    7. et al.
    Stress Doppler echocardiography in relatives of patients with idiopathic and familial pulmonary arterial hypertension: results of a multicenter European analysis of pulmonary artery pressure response to exercise and hypoxia. Circulation 2009;119:1747–57.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Simonneau G,
    2. Montani D,
    3. Celermajer DS,
    4. Denton CP,
    5. Gatzoulis MA,
    6. Krowka M,
    7. et al.
    Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019;53:1801913.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Mathai SC,
    2. Sibley CT,
    3. Forfia PR,
    4. Mudd JO,
    5. Fisher MR,
    6. Tedford RJ,
    7. et al.
    Tricuspid annular plane systolic excursion is a robust outcome measure in systemic sclerosis-associated pulmonary arterial hypertension. J Rheumatol 2011;38:2410–8.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Argiento P,
    2. Chesler N,
    3. Mule M,
    4. D’Alto M,
    5. Bossone E,
    6. Unger P,
    7. et al.
    Exercise stress echocardiography for the study of the pulmonary circulation. Eur Respir J 2010;35:1273–8.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Mathai SC,
    2. Hummers LK,
    3. Champion HC,
    4. Wigley FM,
    5. Zaiman A,
    6. Hassoun PM,
    7. et al.
    Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum 2009;60:569–77.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Fox BD,
    2. Shimony A,
    3. Langleben D,
    4. Hirsch A,
    5. Rudski L,
    6. Schlesinger R,
    7. et al.
    High prevalence of occult left heart disease in scleroderma-pulmonary hypertension. Eur Respir J 2013;42:1083–91.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Allanore Y,
    2. Meune C,
    3. Vonk MC,
    4. Airo P,
    5. Hachulla E,
    6. Caramaschi P,
    7. et al.
    Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis. Ann Rheum Dis 2010;69:218–21.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Sharma T,
    2. Lau EM,
    3. Choudhary P,
    4. Torzillo PJ,
    5. Munoz PA,
    6. Simmons LR,
    7. et al.
    Dobutamine stress for evaluation of right ventricular reserve in pulmonary arterial hypertension. Eur Respir J 2015;45:700–8.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Voilliot D,
    2. Magne J,
    3. Dulgheru R,
    4. Kou S,
    5. Henri C,
    6. Laaraibi S,
    7. et al.
    Determinants of exercise-induced pulmonary arterial hypertension in systemic sclerosis. Int J Cardiol 2014;173:373–9.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. D’Alto M,
    2. Ghio S,
    3. D’Andrea A,
    4. Pazzano AS,
    5. Argiento P,
    6. Camporotondo R,
    7. et al.
    Inappropriate exercise-induced increase in pulmonary artery pressure in patients with systemic sclerosis. Heart 2011;97:112–7.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Tyndall AJ,
    2. Bannert B,
    3. Vonk M,
    4. Airo P,
    5. Cozzi F,
    6. Carreira PE,
    7. et al.
    Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010;69:1809–15.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Parks JL,
    2. Taylor MH,
    3. Parks LP,
    4. Silver RM
    . Systemic sclerosis and the heart. Rheum Dis Clin North Am 2014;40:87–102.
    OpenUrl
  15. 15.↵
    1. Desai CS,
    2. Lee DC,
    3. Shah SJ
    . Systemic sclerosis and the heart: current diagnosis and management. Curr Opin Rheumatol 2011;23:545–54.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Kahan A,
    2. Allanore Y
    . Primary myocardial involvement in systemic sclerosis. Rheumatology 2006;45 Suppl 4:iv14–7.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Hachulla E,
    2. Launay D,
    3. Yaici A,
    4. Berezne A,
    5. de Groote P,
    6. Sitbon O,
    7. et al;
    8. French PAH-SSc Network
    . Pulmonary arterial hypertension associated with systemic sclerosis in patients with functional class II dyspnoea: mild symptoms but severe outcome. Rheumatology 2010;49:940–4.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Reynertson SI,
    2. Kundur R,
    3. Mullen GM,
    4. Costanzo MR,
    5. McKiernan TL,
    6. Louie EK
    . Asymmetry of right ventricular enlargement in response to tricuspid regurgitation. Circulation 1999;100:465–7.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Mukherjee M,
    2. Chung SE,
    3. Ton VK,
    4. Tedford RJ,
    5. Hummers LK,
    6. Wigley FM,
    7. et al.
    Unique abnormalities in right ventricular longitudinal strain in systemic sclerosis patients. Circ Cardiovasc Imaging 2016;9:e003792.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Mukherjee M,
    2. Mercurio V,
    3. Tedford RJ,
    4. Shah AA,
    5. Hsu S,
    6. Mullin CJ,
    7. et al.
    Right ventricular longitudinal strain is diminished in systemic sclerosis compared with idiopathic pulmonary arterial hypertension. Eur Respir J 2017;50:1701436.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Mercurio V,
    2. Mukherjee M,
    3. Tedford RJ,
    4. Zamanian RT,
    5. Khair RM,
    6. Sato T,
    7. et al.
    Improvement in right ventricular strain with ambrisentan and tadalafil upfront therapy in scleroderma pulmonary arterial hypertension. Am J Respir Crit Care Med 2018;197:388–91.
    OpenUrl
  22. 22.↵
    1. Galie N,
    2. Humbert M,
    3. Vachiery JL,
    4. Gibbs S,
    5. Lang I,
    6. Torbicki A,
    7. et al.
    2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016;37:67–119.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Mathai SC,
    2. Bueso M,
    3. Hummers LK,
    4. Boyce D,
    5. Lechtzin N,
    6. Le Pavec J,
    7. et al.
    Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension. Eur Respir J 2010;35:95–104.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Coghlan JG,
    2. Denton CP,
    3. Grünig E,
    4. Bonderman D,
    5. Distler O,
    6. Khanna D,
    7. et al;
    8. DETECT study group
    . Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 2014;73:1340–9.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Allanore Y,
    2. Wahbi K,
    3. Borderie D,
    4. Weber S,
    5. Kahan A,
    6. Meune C
    . N-terminal pro-brain natriuretic peptide in systemic sclerosis: a new cornerstone of cardiovascular assessment? Ann Rheum Dis 2009;68:1885–9.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Kovacs G,
    2. Herve P,
    3. Barbera JA,
    4. Chaouat A,
    5. Chemla D,
    6. Condliffe R,
    7. et al.
    An official European Respiratory Society statement: pulmonary haemodynamics during exercise. Eur Respir J 2017;50:1700578.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 47, Issue 5
1 May 2020
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Exercise Echocardiography as a Screening Tool in Systemic Sclerosis
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Exercise Echocardiography as a Screening Tool in Systemic Sclerosis
MONICA MUKHERJEE, STEPHEN C. MATHAI
The Journal of Rheumatology May 2020, 47 (5) 643-645; DOI: 10.3899/jrheum.191249

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Exercise Echocardiography as a Screening Tool in Systemic Sclerosis
MONICA MUKHERJEE, STEPHEN C. MATHAI
The Journal of Rheumatology May 2020, 47 (5) 643-645; DOI: 10.3899/jrheum.191249
del.icio.us logo Twitter logo Facebook logo  logo Mendeley logo
  • Tweet Widget
  •  logo
Bookmark this article

Jump to section

  • Article
    • Footnotes
    • REFERENCES
  • Info & Metrics
  • References
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Reversing the Tide of the Growing Burden of Avoidable Musculoskeletal Pain and Disability
  • Interferon Response Gene Score in Juvenile Dermatomyositis
  • Revisiting Magnetic Resonance Imaging Structural Lesions in the Sacroiliac Joints
Show more Editorial

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2025 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire